Semaglutide attenuates diabetic vascular calcification by enhancing autophagy and lysosomal function via targeting CPNE1
Diabetic patients are highly susceptible to vascular calcification, a pathological process lacking specific therapies. Semaglutide, a Glucagon-like peptide-1 receptor agonist (GLP-1RA), provides cardiovascular protection, but its direct effect on diabetic vascular calcification (DVC) and the underlying mechanisms...